Timing of Carbetocin Administration in Postpartum Hemorrhage

Launched by MEHMET METE KIRLANGIÇ · Jan 10, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating the use of a medication called carbetocin to prevent postpartum hemorrhage (PPH), which is heavy bleeding after childbirth. PPH can be a serious issue, and this study aims to determine the best timing for administering carbetocin to help reduce the risk of this condition. Carbetocin is a long-acting form of oxytocin, a hormone that helps with uterine contractions and can be beneficial in managing bleeding. The trial will compare different timings of carbetocin administration to see which is most effective and safe for new mothers.

To participate in this trial, women must be having their first baby (primiparous) and have a vaginal delivery at or after 38 weeks of pregnancy. Unfortunately, some women may not be eligible due to certain health conditions or risk factors, such as high blood pressure, asthma, or if they have had previous surgeries that affect the uterus. The trial is currently not recruiting participants, but once it begins, eligible women can expect close monitoring and support to assess how well carbetocin works in preventing postpartum hemorrhage.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Singleton pregnancy
• • Vaginal delivery at or beyond 38 weeks of gestation
• • Primipar
• Exclusion Criteria:
• • Multiparity
• • Contraindications to carbetocin use (e.g., pre-existing hypertension, pre-eclampsia,asthma, cardiac, renal, or liver disease)
• • High-risk factors for primary postpartum hemorrhage, including grand multiparity,presence of uterine fibroids, or a need for prophylactic oxytocin infusion
• • Anemia or
• • body mass index (BMI) over 35
• • Baby weight over 4000 grams
• • Comorbidities or chronic diseases
• • History of curettage
• • Use of propess or oxytocin during labor